Table 1.
Clinical Characteristics for all men and by SPINK1 expression status among 879a men treated with radical prostatectomy for prostate cancer, Physicians’ Health Study and Health Professionals Follow-up Study cohorts
| Characteristic | All Men | SPINK1 Negative | SPINK1 Positive | Pb |
|---|---|---|---|---|
| Number | 879 | 805 | 74 | |
| Mean Follow-Up Time, years (SDc) | 13.5 (4.6) | 13.4 (4.6) | 13.6 (4.5) | 0.78 |
| Mean Age at Diagnosis, years (SD) | 65.4 (6.0) | 65.4 (6.0) | 65.0 (6.2) | 0.54 |
| Median PSA at Diagnosis, ng/ml (IQRd) | 7.0 (5.6) | 7.0 (5.6) | 7.0 (7.5) | 0.88 |
| Tumor Stage, n (%) | ||||
| pT2 N0/Nx | 599 (71) | 547 (71) | 52 (71) | |
| pT3 N0/Nx | 222 (26) | 204 (26) | 18 (25) | |
| pT4/N1/M1 | 26 (3) | 23 (3) | 3 (4) | 1.00 |
| Gleason Score, n (%) | ||||
| 2–6 | 185 (21) | 173 (21) | 12 (16) | |
| 3+4 | 325 (37) | 298 (37) | 27 (36) | |
| 4+3 | 214 (24) | 194 (24) | 20 (27) | |
| 8–10 | 155 (18) | 140 (17) | 15 (20) | 0.25 |
| Lethal Prostate Cancere, n (%) | ||||
| No | 804 (91) | 735 (91) | 69 (93) | |
| Yes | 75 (9) | 70 (9) | 5 (7) | 0.57 |
| Biochemical Recurrence, n (%) | ||||
| No | 666 (76) | 612 (76) | 54 (73) | |
| Yes | 213 (24) | 193 (24) | 20 (27) | 0.56 |
| All Cause Mortalityf, n (%) | ||||
| No | 619 (70) | 568 (71) | 51 (69) | |
| Yes | 260 (30) | 237 (29) | 23 (31) | 0.77 |
| Ki67 expression, median (IQR)g | 0. 12 (0.45) | 0. 12 (0.45) | 0.11 (0.39) | 0.70 |
| TUNEL, median (IQR)h | 0.5 (2.0) | 0.5 (2.0) | 0.5 (2.0) | 0.11 |
| ERG negative, n | 427 | 380 | 47 | |
| ERG positive, n | 427 | 408 | 19 | 0.0003 |
Numbers may not add up to 879 because men with missing information for a characteristic are not included in that characteristic.
P-values are based on the following tests: t-test for follow-up time and age at diagnosis; Wilcoxon rank sums test for PSA at diagnosis, Ki67 expression, and TUNEL; exact Cochran-Armitage trend test for tumor stage, Cochran-Armitage trend test for Gleason sum; Chi-square test for lethal prostate cancer, biochemical recurrence, all-cause mortality, and ERG status.
SD: standard deviation.
IQR: inter-quartile range.
Lethal prostate cancer includes metastases to distant organs, and prostate cancer death.
All-cause mortality includes prostate cancer death and death due to any other cause
Ki67 expression was available for 778 men with known SPINK1 status.
TUNEL was available for 675 men with known SPINK1 status.